OncoMatch/Clinical Trials/NCT04138719
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer
Is NCT04138719 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nab-paclitaxel + Carboplatin and Nab-paclitaxel + Epirubicin for breast cancer.
Treatment: Nab-paclitaxel + Carboplatin · Nab-paclitaxel + Epirubicin — This is a multicenter, open, randomized, comparison study. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have \<1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. Neoadjuvant therapy is often used to reduce the size of tumors, especially in locally advanced tumors. The purpose of this therapy is to make part of patients operable and to facilitate breast-conserving surgery. The purpose of this study is to assess the efficacy and safety of the following two proposals: nab-paclitaxel plus carboplatin versus nab-paclitaxel plus epirubicin, in order to provide support for rational clinical application. The total number of patients to be included in this study is 520 patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Previous treatment with any cytotoxic chemotherapy
Cannot have received: endocrine therapy
Previous treatment with any...endocrine therapy
Cannot have received: biotherapy
Previous treatment with any...biotherapy
Cannot have received: radiation therapy
Previous treatment with any...radiotherapy
Lab requirements
Blood counts
neutrophils (≥1.5×10^9/l), platelets (≥100×10^9/l), hemoglobin (≥90 g/l)
Kidney function
serum creatinine≤ 1.5×institutional upper limit of normal (uln)
Liver function
ast and alt ≤ 2.5 × uln; total bilirubin≤1.5×uln, or patients with gilbert's syndrome ≤ 2.5 × uln
Cardiac function
lvef≥55%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify